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Abstract
Introduction
The ablation gaps have been known as the main mechanism of recurrence as atrial tachy-
cardia (AT) rather than atrial fibrillation (AF) after AF catheter ablation. However, AF organi-
zation due to reduction of critical mass or focal trigger may also be the mechanism of AT
recurrence. We sought to find out the main clinical factors of recurrence as AT rather than
AF after AF ablation in the absence of antiarrhythmic drug effect.
Methods
We analyzed 521 patients (70.8% men, 64.1% paroxysmal AF) who experienced AT or AF
recurrence without antiarrhythmic drug effect during 44.7 ± 25.4 months follow-up.
Results
Among 521 patients with recurrence, 42.0% (219 of 521) recurred with AT. The proportion
of AT recurrence was not different between the pulmonary vein isolation only group and
additional linear ablation group (45.1% vs. 38.1%, p = 0.128). The absence of hypertension
(odds ratio [OR] 0.49, 95% confidence interval [CI] 0.29–0.83, p = 0.007), small left atrial
(LA) volume index (OR 0.89 per 10 mL/m2, 95% CI 0.79–1.00, p = 0.049), and high mean
LA bipolar voltage (OR 2.03 per 1 mV, 95% CI 1.30–3.16, p = 0.002) were independently
associated with AT recurrence, whereas additional linear ablation was not. Among 90
patients who underwent repeat ablation procedure, rates of PV reconnection (p = 0.358)
and gap in prior linear ablations (p = 0.269) were not significantly different between AT recur-
rence group and AF recurrence group.
Conclusion
The degree of LA remodeling is significantly associated with recurrence as AT after AF abla-
tion, irrespective of potential ablation gap in linear lesion.
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Introduction
Atrial fibrillation (AF) is one of the most commonly diagnosed cardiac arrhythmias, which is
associated with diverse disease mechanisms and comorbidities, most importantly with the degen-
erative process associated with aging. Symptomatic patients with drug-refractory AF are proven
candidates for rhythm control with radiofrequency catheter ablation (RFCA). Although RFCA is
very effective in controlling AF rhythm, a significant number of patients develop recurrence,[1]
and some of patients develop organized atrial tachycardia (AT) rather than AF after RFCA of AF.
[2, 3] However, it is unclear whether technical failure or AF progression is the distinctive mecha-
nism of recurrence,[4] and which clinical factors are the main determinants of recurrence patterns
(AT or AF). Previous studies suggested that a small electrical gap along the ablation line results in
a conduction delay in the atrium, which generates an excitable gap that might present as stable
macro-reentrant AT, and that incomplete conduction block of linear ablation increases the risk of
recurrent AT.[5] However, atrial tissue size and remodeling may also affect the type of atrial
arrhythmias. Haissaguerre et al.[6, 7] suggested that a stepwise approach to persistent AF may
increase the AF cycle length, organize the AF pattern, and finally cause the transformation of AF
to AT, followed by termination of arrhythmia. Critical mass reduction by linear ablation may
reduce wavebreak and inhibit AF maintenance,[8] eventually resulting in recurrence as AT
instead of disorganized AF even though there was no electrical gap in linear ablation lesions.
Atrial structural remodeling secondary to AF disease progression has also been suggested as a
determinant of recurrence type after AF ablation.[9] Another important factor in recurrence type
after AF ablation is focal trigger.[10] Lastly, antiarrhythmic drugs, especially sodium channel
blockers, can influence the type of recurrence, too.[11] Therefore, the aim of this study was to
investigate what clinical factors are the main determinants of recurrence patterns (AT vs. AF)
after AF ablation, in the absence of antiarrhythmic drug effect.
Methods
Study population
The study protocol adhered to the principles of the Declaration of Helsinki and was approved
by the Institutional Review Board at the Yonsei University Health System. All patients provided
written informed consent for inclusion in the Yonsei AF Ablation Cohort Database (Clinical-
trials.gov; NCT02138695). Between March 2009 and December 2016, a total of 2,158 patients
underwent RFCA for AF, and 1,023 consecutive patients with AF who experienced early or late
recurrence after RFCA were screened from this cohort. According to published guidelines,[12]
episodes of AT or AF lasting 30 seconds or more after catheter ablation of AF were considered
as recurrence. Among the 1,023 patients, 521 patients (369 [70.8%] men, 334 [64.1%] paroxys-
mal AF) who were not receiving antiarrhythmic drugs at the time of recurrence were included
in this study after excluding 502 patients with following criteria: 1) those with history of prior
RFCA or cardiac surgery (n = 140), 2) those with valvular AF (moderate to severe mitral steno-
sis, any mechanical or bioprosthetic heart valve, or mitral valve repair; n = 43), 3) those with
potential antiarrhythmic drug effect at the time of recurrence (n = 282), and 4) those who both
types of recurrence (AT and AF) were documented after RFCA (n = 37).
Electrophysiologic mapping and CT measurement of the left atrium
Details regarding electrophysiologic mapping and the RFCA technique and strategy were per-
formed as described in previous studies.[9, 13] The left atrial (LA) voltage map was generated
during de novo RFCA by recording contact bipolar electrograms from 350–500 points on the
LA endocardium during right atrium pacing at a constant cycle length of 500 ms. LA voltage
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values were obtained by experienced operators only at secure endocardial contact points, and
contact artifacts and noises were excluded in the LA voltage analysis. The mean LA voltage
was calculated as described previously.[9] The three-dimensional (3D) spiral CT images of the
LA were analyzed before the de novo procedure in an imaging processing workstation (Aquar-
ius, Terarecon Inc., Foster City, CA, USA). LA images were subdivided into compartments
according to the embryological origin as follows: venous LA, anterior LA, and LA appendage.
Radiofrequency catheter ablation
We used an open irrigated-tip catheter (Celsius, Johnson & Johnson Inc., Diamond Bar, CA,
USA; Coolflex, St. Jude Medical Inc., Minnetonka, MN, USA; 30–35 W; 42˚C) to deliver radiofre-
quency (RF) energy for ablation. The ablation RF power setting was 30–35 W; however, it was
25–30 W for the posterior wall to prevent potential complications. All patients initially underwent
circumferential pulmonary vein isolation (CPVI) and the cavotricuspid isthmus (CTI) ablation.
The end-point of CPVI was entrance and exit block of pulmonary vein (PV) conduction. For
patients with persistent AF, we added a roof line, posterior inferior line, and anterior line as opera-
tor’s discretion. The operator was also able to choose to either perform additional ablations in the
superior vena cava or non-PV foci, or conduct the complex fractionated electrogram-guided abla-
tion at his/her discretion. The procedure was considered complete when there was no immediate
recurrence of AF after cardioversion with isoproterenol infusion (5 μg/min). If there were AF trig-
gers or atrial premature beats that could be mapped, we carefully mapped and ablated the non-PV
foci as much as possible. All RFCA procedures were conducted according to the above-mentioned
specific protocol by two operators with over 10 years of experience.
Follow-up after ablation
Patients visited the outpatient clinic 1, 3, 6, and 12 months after RFCA and every 6 months
thereafter. An ECG was obtained at every visit. A 24-hour Holter ECG monitor or an event
recorder was worn at 3, 6, 12, 18, and 24 months as a minimum requirement according to the
guidelines.[12] Additional ECG, Holter monitor recording, or event monitor recording was
obtained when the patient’s symptoms were suggestive of AF recurrence.
AT mapping in repeat ablation procedure
If the patient maintained sinus rhythm at the beginning of 2nd ablation procedure, we checked
block states of previous ablation sites by differential pacing, and then achieved bidirectional
blocks by filling the gap. If the initial rhythm was AF, we cardioverted the patient, and repeat
above mapping and ablation procedure. In patients with sustaining organized AT, we acquired
3D-activation map first, and defined the conduction gaps of previous ablation sites. We differ-
entiated the mechanism of tachycardia by multi-site entrainment mapping maneuver.[14] If
AT morphology changed during RF energy delivery, we mapped multiple ATs one by one con-
secutively. After AT termination, we evaluated block states of previous ablation sites, and
achieved bidirectional blocks. As the final step of repeat ablation, we tested immediate recur-
rence of AF/AT after cardioversion with isoproterenol infusion as described above, and
mapped and ablated the non-PV foci as much as possible.
Statistical analysis
Continuous variables are presented as means ± standard deviations, and they were compared
using Student’s t-test. Categorical variables are reported as frequencies (percentages), and they
were compared using the Fisher’s exact test. Multivariate logistic regression analysis was
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performed for the identifiable predictors of recurrence as AT. A p-value<0.05 was considered
to be statistically significant. Statistical analyses were performed using SPSS version 23.0.
Results
Patient characteristics and recurrence as AT
This study included 521 patients with antiarrhythmic drug-free recurrence after de novo AF
ablation. The baseline characteristics of the patients and comparisons according to the type of
recurrence are presented in Table 1. The mean age of the patients was 59.3 ± 10.7 years old,
70.8% were male, and 64.1% had paroxysmal AF. Among 521 patients who showed recurrence
in the absence of antiarrhythmic drug, 219 patients (42.0%) recurred as AT and remaining 302
patients (58.0%) recurred as AF. Patients with recurrent AT had a higher prevalence of parox-
ysmal AF (p = 0.007), a lower prevalence of hypertension (p = 0.006), smaller LA volume
(p<0.001) and LA volume index (p = 0.002) measured by CT, and higher mean LA bipolar
voltage (measured in 355 patients, p<0.001) compared to those with recurrent AF.
Table 1. Patient’s characteristics according to type of recurrence (AT vs. AF).
Overall
(n = 521)
Recurrence as AT (n = 219) Recurrence as AF (n = 302) p value
Age (years) 59.3 ± 10.7 59.7 ± 10.9 58.9 ± 10.6 0.393
Male 369 (70.8%) 157 (71.7%) 212 (70.2%) 0.770
Paroxysmal AF 334 (64.1%) 155 (70.8%) 179 (59.3%) 0.007
BMI (kg/m2) 25.1 ± 2.9 24.8 ± 2.8 25.2 ± 3.0 0.119
CHA2DS2-VASc score 1.80 ± 1.6 1.74 ± 1.59 1.84 ± 1.63 0.493
Heart failure 35 (6.7%) 13 (5.9%) 22 (7.3%) 0.598
Hypertension 244 (46.8%) 87 (39.7%) 157 (52.0%) 0.006
Diabetes 85 (16.3%) 37 (16.9%) 48 (15.9%) 0.811
Stroke/TIA 66 (12.7%) 28 (12.8%) 38 (12.6%) 0.999
Vascular disease 83 (15.9%) 32 (14.6%) 51 (16.9%) 0.545
Echocardiographic parameters
LA size (mm) 41.8 ± 6.2 41.3 ± 6.2 42.1 ± 6.2 0.132
LAVI (ml/m2) 37.5 ± 13.2 36.6 ± 13.6 38.2 ± 12.9 0.187
LVEF (%) 63.1 ± 7.8 63.2 ± 6.9 63.0 ± 8.3 0.778
E/Em 10.4 ± 4.0 10.1 ± 3.6 10.6 ± 4.3 0.152
Cardiac CT parameters
LV volume (mL) 149.9 ± 42.4 141.5 ± 42.6 156.1 ± 41.3 <0.001
LA volume index (ml/m2) 83.4 ± 24.1 79.2 ± 24.2 86.6 ± 23.7 0.002
Venous atrium volume index 27.7 ± 9.3 26.5 ± 9.2 28.5 ± 9.3 0.023
LA appendage volume index 6.9 ± 3.0 6.7 ± 2.9 7.1 ± 3.2 0.183
Anterior LA volume index 48.9 ± 15.3 46.0 ± 15.2 51.0 ± 15.1 <0.001
Mean LA bipolar voltage (mV) (n = 355) 1.14 ± 0.61 1.27 ± 0.64 1.03 ± 0.56 <0.001
Baseline Medications
ACEi/ARB 177 (34.0%) 65 (29.7%) 112 (37.2%) 0.092
β-blocker 166 (31.9%) 65 (29.7%) 101 (33.6%) 0.392
Statin 154 (29.6%) 61 (27.9%) 93 (30.9%) 0.497
Data are expressed as n (%) or mean ± standard deviation.
ACEi = angiotensin converting enzyme inhibitor; AF = atrial fibrillation; ARB = angiotensin receptor blocker; AT = atrial tachycardia; CT = computed
tomography; E/Em = ratio of mitral peak velocity of early filling (E) to early diastolic mitral annular velocity (Em); LA = left atrial; LVEF = left ventricular
ejection fraction; TIA = transient ischemic attack.
https://doi.org/10.1371/journal.pone.0188326.t001
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Procedural characteristics of de novo ablation according to type of
recurrence
On procedure-related characteristics (Table 2), ablation lesion set, proportion or number of
additional linear ablation, and its bidirectional block rates were not significantly different
between patients with recurrent AT and those with recurrent AF. However, ablation time
(p = 0.046) and procedure time (p = 0.015) was longer in patients with recurrent AT compare
to those with recurrent AF. Follow-up duration was 44.7 ± 25.4 months (median: 43 months).
Timing of recurrence was 20.8 ± 16.8 months after RFCA (median: 16 months). Early recur-
rence (recurrence within 3 months) was more frequent in patients with recurrent AT compare
to those with recurrent AF (p = 0.012). But late recurrence (recurrence after 3 months) was
less observed in patients with recurrent AT (p = 0.002). Fig 1 showed the proportion of recur-
rence as AT in total recurrence according to lesion set of de novo ablation and number of addi-
tional linear ablations. The proportion of recurrence as AT was not different between CPVI
only group (n = 295) and CPVI + additional linear ablation group (n = 226). Number of addi-
tional linear ablations also did not influence the proportion of recurrence as AT.
Less remodeled LA rather than linear ablation is associated with AT
recurrence
In multivariate logistic regression analysis for recurrence as AT (Table 3), old age (odds ratio
[OR] 1.03, 95% confidence interval [CI] 1.01–1.05, p = 0.008), absence of hypertension (OR
Table 2. Procedural characteristics of de novo ablation according to type of recurrence (AT vs. AF).
Overall
(n = 521)
Recurrence as AT (n = 219) Recurrence as AF (n = 302) p value
Ablation time (sec) 5003.8 ± 1659.5 5174.5 ± 1644.4 4880.1 ± 1662.1 0.046
Procedure time (sec) 188.4 ± 53.0 195.0 ± 53.4 183.6 ± 52.3 0.015
Additional linear ablation a 226 (43.4%) 86 (39.3%) 140 (46.4%) 0.128
Roof line 222 (42.6%) 86 (39.3%) 136 (45.0%) 0.209
Postero-inferior line 169 (32.4%) 70 (32.0%) 99 (32.8%) 0.850
Anterior line 177 (34.0%) 65 (29.7%) 112 (37.1%) 0.092
Number of additional linear ablation a 1.17 ± 1.42 1.06 ± 1.39 1.25 ± 1.43 0.127
CFAE ablation 30 (5.8%) 13 (5.9%) 17 (5.6%) >0.999
CTI ablation 480 (92.1%) 207 (94.5%) 273 (90.4%) 0.100
Bidirectional block rates b of additional linear ablation
Roof line 158/222 (71.2%) 62/86 (72.1%) 96/136 (70.6%) 0.880
Postero-inferior line 73/169 (43.2%) 27/70 (38.6%) 46/99 (46.5%) 0.346
Anterior line 88/177 (49.7%) 30/65 (46.2%) 58/112 (51.8%) 0.534
Bidirectional block rate of CTI 480/480 (100%) 207/207 (100%) 273/273 (100%) >0.999
Follow-up duration (months) 44.7 ± 25.4 45.4 ± 25.5 44.3 ± 25.4 0.611
Early recurrence c 339 (65.1%) 156 (71.2%) 183 (60.6%) 0.012
Late recurrence d 268 (51.4%) 95 (43.4%) 173 (57.3%) 0.002
Data are expressed as n (%) or mean ± standard deviation.
aAdditional linear ablation includes the following three lesions: roof line ablation, postero-inferior line ablation, and anterior line ablation.
bValues are expressed as the number of confirmed bidirectional blocks divided by the number of linear ablations.
cEarly recurrence: recurrence within 3 months.
dLate recurrence: recurrence after 3 months.
AF = atrial fibrillation; AT = atrial tachycardia; CFAE = complex fragmented atrial electrogram; CTI = cavotricuspid isthmus.
https://doi.org/10.1371/journal.pone.0188326.t002
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0.53, 95% CI 0.35–0.81, p = 0.004), and small LA volume index by CT (OR 0.86 per 10 mL/m2,
95% CI 0.78–0.94, p = 0.001) were independently associated with recurrent AT, while addi-
tional linear ablation was not (model 1). Among 355 patients with available LA bipolar voltage
data (model 2), high LA bipolar voltage (OR 2.03, 95% CI 1.30–3.16, p = 0.002) was also
Fig 1. The proportion of recurrence as AT in total recurrence according to lesion set of de novo
ablation and number of additional linear ablations. AF = atrial fibrillation; AT = atrial tachycardia;
CPVI = circumferential pulmonary vein isolation.
https://doi.org/10.1371/journal.pone.0188326.g001
Table 3. Logistic regression analysis for clinical variables predictive of recurrence as AT (analysis including both early a and late b recurrence,
n = 521).
Univariate Analysis Multivariate model 1 c Multivariate model 2 d
OR 95% CI p value OR 95% CI p value OR 95% CI p value
Age (per year) 1.01 0.99–1.02 0.393 1.03 1.01–1.05 0.008 1.03 1.00–1.05 0.058
Male 0.93 0.63–1.37 0.712
Paroxysmal AF 1.66 1.15–2.41 0.007
Heart failure 1.25 0.61–2.53 0.544
Hypertension 0.61 0.43–0.87 0.006 0.53 0.35–0.81 0.004 0.49 0.29–0.83 0.007
Diabetes 0.93 0.58–1.49 0.773
CHA2DS2-VASc score 0.96 0.86–1.07 0.492
LVEF 1.00 0.98–1.03 0.778
E/Em 0.97 0.93–1.01 0.154
LA volume index by CT (per 10mL/m2) 0.88 0.81–0.95 0.002 0.86 0.78–0.94 0.001 0.89 0.79–1.00 0.049
Mean LA bipolar voltage (per 1mV) 1.97 1.37–2.83 <0.001 2.03 1.30–3.16 0.002
Ablation time (per 60 sec) 1.01 1.00–1.01 0.063
Additional linear ablation 0.75 0.53–1.07 0.107
aEarly recurrence: recurrence within 3 months.
bLate recurrence: recurrence after 3 months.
cModel 1: age, sex and clinical variables that had statistical significance for univariate analysis (paroxysmal AF, hypertension, and LA volume index by CT)
except mean LA bipolar voltage.
dModel 2: variables in the model 1 + LA bipolar voltage (measured in 355 patients).
AF = atrial fibrillation; AT = atrial tachycardia; CI = confidence interval; CT = computed tomography; E/Em = ratio of mitral peak velocity of early filling (E) to
early diastolic mitral annular velocity (Em); LA = left atrial; LVEF = left ventricular ejection fraction; OR = odds ratio.
https://doi.org/10.1371/journal.pone.0188326.t003
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significantly associated with recurrent AT. Fig 2 shows representative examples of LA voltage
maps. In consistence, patients with late recurrence after 3 months of RFCA (n = 269), the
absence of hypertension (OR 0.47, 95% CI 0.23–0.99, p = 0.049) and high LA bipolar voltage
(OR 3.03, 95% CI 1.56–5.88, p = 0.001) were independently associated with recurrent AT
(Table 4). However, none of the logistic regression analyses mentioned above showed any rela-
tionship between recurrent AT and additional linear ablation.
Repeat ablation findings according to type of recurrence
Out of 521 patients, we conducted repeat ablation procedures in 90 patients (17.3%, Table 5).
Of these patients with repeat ablation, 50.0% (45) were recurred as AT after de novo
Fig 2. Typical examples of patients with recurrent AT and recurrent AF. Patients with recurrent AT (A)
have a relatively smaller LA volume index and higher mean LA bipolar voltage than patients with
recurrent AF (B). AT = atrial tachycardia; AF = atrial fibrillation; CT = computed tomography; LA = left atrial.
https://doi.org/10.1371/journal.pone.0188326.g002
Table 4. Logistic regression analysis for clinical variables predictive of recurrence as AT (analysis including only late a recurrence, n = 269).
Univariate Analysis Multivariate model 1 b Multivariate model 2 c
OR 95% CI p value OR 95% CI p value OR 95% CI p value
Age (per year) 1.01 0.99–1.04 0.227 1.03 1.00–1.06 0.051 1.03 0.99–1.07 0.077
Male 1.13 0.65–1.97 0.664
Paroxysmal AF 1.53 0.90–2.59 0.114 1.73 0.95–3.13 0.071
Heart failure 0.75 0.26–2.20 0.600
Hypertension 0.73 0.44–1.20 0.211 0.53 0.29–0.98 0.043 0.47 0.23–0.99 0.049
Diabetes 1.83 0.94–3.56 0.075
CHA2DS2-VASc score 1.04 0.88–1.22 0.674
LVEF 1.02 0.99–1.06 0.255
E/Em 1.01 0.94–1.08 0.840
LA volume index by CT (per 10mL/m2) 0.97 0.87–1.09 0.619
Mean LA bipolar voltage (per 1mV) 2.23 1.33–3.75 0.002 3.03 1.56–5.88 0.001
Ablation time (per 60 sec) 1.01 1.00–1.02 0.055
Additional linear ablation 1.12 0.68–1.84 0.669
aLate recurrence: recurrence after 3 months.
bModel 1: age, sex, paroxysmal AF, hypertension, and LA volume index by CT.
cModel 2: variables in the model 1 + LA bipolar voltage (measured in 186 patients).
AF = atrial fibrillation; AT = atrial tachycardia; CI = confidence interval; CT = computed tomography; E/Em = ratio of mitral peak velocity of early filling (E) to
early diastolic mitral annular velocity (Em); LA = left atrial; LVEF = left ventricular ejection fraction; OR = odds ratio.
https://doi.org/10.1371/journal.pone.0188326.t004
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procedure. There was no difference in rates of PV reconnection (75.6% vs. 64.4%, p = 0.358),
gaps in prior additional linear ablations of LA (90.5% vs. 76.9%, p = 0.269), and gap in prior
CTI ablation (31.0% vs. 22.7%, p = 0.468) between recurrent AT group and recurrent AF
group. At the beginning of repeat procedure, there were 40 cases in which organized AT was
maintained. The mechanisms of ATs were macroreentry in 62.5% (25/40), focal or micro-
reentry in 20.0% (8/40), and unmappable due to termination or degeneration to AF in 17.5%
(7/40). However, there was no significant difference in frequency of PV reconnection (p =
0.358) and previous linear ablation gap (p = 0.269) between recurrent AT group and recurrent
AF group (Table 5). Outcome of repeat ablation was better in patients with recurrent AT com-
pared to those with recurrent AF (p = 0.006; Fig 3).
Discussion
Main findings
In this study, we found that a small LA volume index and high mean LA bipolar voltage, rather
than the additional linear ablation in de novo AF ablation, were independently associated with
Table 5. Comparison of redo ablation findings according to type of recurrence (AT vs. AF) after de novo AF ablation.
Overall (n = 90) Recurrence as AT (n = 45) Recurrence as AF (n = 45) p value
Time to the second ablation (months) 25.9 ± 21.1 24.3 ± 22.9 27.5 ± 19.4 0.472
Age 57.0 ± 9.8 56.8 ± 10.2 57.2 ± 9.5 0.823
Male 65 (72.2%) 31 (68.9%) 34 (75.6%) 0.638
Paroxysmal AF 64 (71.1%) 35 (77.8%) 29 (64.4%) 0.245
Number of patients with PV reconnection 63 (70.0%) 34 (75.6%) 29 (64.4%) 0.358
Left superior PV 47 (52.2%) 25 (55.6%) 22 (48.9%) 0.673
Left inferior PV 34 (37.8%) 18 (40.0%) 16 (35.6%) 0.828
Right superior PV 37 (41.1%) 18 (40.0%) 19 (42.2%) >0.999
Right inferior PV 36 (40.0%) 16 (35.6%) 20 (44.4%) 0.519
Number of reconnected PVs per patient 1.71 ± 1.49 1.71 ± 1.39 1.71 ± 1.59 >0.999
Gap in prior additional linear ablations a 39/47 (83.0%) 19/21 (90.5%) 20/26 (76.9%) 0.269
Roof line 17/47 (36.2%) 7/21 (33.3%) 10/26 (38.5%) 0.768
Posterior-inferior line 25/38 (65.8%) 11/14 (78.6%) 14/24 (58.3%) 0.294
Anterior line 21/35 (60.0%) 7/10 (70.0%) 14/25 (56.0%) 0.704
Gap in prior CTI ablation 23/86 (26.7%) 13/42 (31.0%) 10/44 (22.7%) 0.468
Documented ATs during procedure 40 28 12
Macro-reentrant 25 (62.5%) 20 (71.4%) 5 (41.7%) 0.091
Gap-related AT b 6 (15.0%) 5 (17.9%) 1 (8.3%) 0.648
CTI-dependent AFL 5 (12.5%) 3 (10.7%) 2 (16.7%) 0.627
Perimitral AFL 8 (20.0%) 6 (21.4%) 2 (16.7%) >0.999
Roof-dependent reentry 1 (2.5%) 1 (3.6%) 0 (0.0%) >0.999
Other macro-reentry 5 (12.5%) 5 (17.9%) 0 (0.0%) 0.298
Focal / micro- reentrant 8 (20.0%) 4 (14.3%) 4 (33.3%) 0.211
PV related AT 2 (5.0%) 2 (7.1%) 0 (0.0%) >0.999
Non-PV trigger AT 6 (15.0%) 2 (7.1%) 4 (33.3%) 0.055
Unmappable due to termination 7 (17.5%) 4 (14.3%) 3 (15.0%) 0.410
Data are expressed as n (%) or mean ± standard deviation.
aValues are expressed as the number of non-blocked linear ablations divided by the number of prior linear ablations.
bGap-related AT means that AT re-entry circuit traverses a prior linear ablation line.
AF = atrial fibrillation; AFL = atrial flutter; AT = atrial tachycardia; CTI = cavotricuspid isthmus; PV = pulmonary vein.
https://doi.org/10.1371/journal.pone.0188326.t005
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recurrence as AT after catheter ablation of AF. In the sub-analysis of repeat ablation findings,
frequency of PV reconnection or previous linear ablation gap was not significantly different
between patients with recurrent AT and those with recurrent AF.
Mechanism of AT after AF ablation
Why do some patients experience recurrence as AT and others as AF? Fibrillation mainte-
nance requires an appropriate critical mass size [8] as well as a short wavelength.[15, 16] The
presence of critical mass in atria has been reported in a large animal study,[17] simulation
study,[18] and clinical studies.[8] Therefore, less remodeled atrium has low critical mass,
appropriate refractoriness, and robust atrial conduction, resulting in lower chance of waveb-
reak and fibrillatory conduction after CPVI, which favors an AT recurrence pattern. In con-
trast, patients with significant remodeling and scattered focal atrial scars have a reasonable
chance of wavebreak and recurrence as AF, which is triggered from non-PV foci, even after
appropriate critical mass reduction.[19] In our study, a large LA volume and low LA voltage,
which suggest a more structurally and electrically remodeled LA, were significantly associated
with recurrent AF. Although the electrical gap due to incomplete conduction block has been
suggested to be one of the important mechanisms of recurrent AT after AF ablation in previ-
ous studies,[4, 20] most of those studies were performed after de novo ablation with a non-
Fig 3. Free from atrial arrhythmias after the redo ablation according to recurrence type of the de novo
ablation. AF = atrial fibrillation; AT = atrial tachycardia.
https://doi.org/10.1371/journal.pone.0188326.g003
Recurrence as AT after AF ablation
PLOS ONE | https://doi.org/10.1371/journal.pone.0188326 November 16, 2017 9 / 12
irrigated tip catheter. However, at present, the use of an irrigated tip catheter has become the
standard ablation technique for AF. An irrigated tip catheter can make deeper ablation lesions
because it can deliver more energy to the tissue than a non-irrigated tip catheter. Because of
this improvement of the catheter, the bidirectional conduction block can be made more effec-
tive now and the electrical gap due to incomplete conduction block decreased compared to the
past. In the present study, we attempted to generate bidirectional block as much as possible
with an irrigated tip catheter in all cases, and the proportion of patients who showed no PV
potential at redo ablation was 30.0%. In the redo ablation procedure, only 20.0% of presented
ATs were related to prior ablation gaps (15.0% related to prior linear ablation gap, 5.0% related
to prior PV ablation gap), but majority (62.5%) of presented ATs were not gap-related AT
(macro-reentrant AT unrelated to prior linear ablation lesions: 47.5%, non-PV trigger AT:
15.0%). Remaining 17.5% of ATs were not mappable because they were terminated or changed
to AF.
Disease specific recurrence type after AF ablation
Hypertension is known to increase the risk of AF by about two-fold, and proven to be associ-
ated with early and progressive changes in atrial remodeling.[21] The magnitude of structural
remodeling of LA is associated with hypertension, and antihypertensive treatments are associ-
ated with regression of left ventricular hypertrophy and decreased incidence of new-onset AF
episodes.[22, 23] In this study, hypertension was a significant predictor for recurrence as AF
rather than recurrence as AT. This might be related to aorto-ventricular and ventriculo-atrial
hemodynamic couplings: High central blood pressure results in left ventricular hypertrophy as
well as reduced diastolic function,[24] while reduced left ventricular diastolic function
increases LA pressure and LA remodeling and reduces LA compliance and voltage.[25] Hyper-
tension-related electroanatomical changes have LA vulnerable to AF rather than AT, when
they recur after catheter ablation.
However, the results of current study might be limited to the patients with non-valvular AF
with mild to moderate degree of atrial remodeling. In patients with huge atrium with large
atrial scar, such as rheumatic AF or valvular AF, most of atrial arrhythmias presented as AT or
organized AF. In those patients, slow conduction velocity, short wavelength, and large scar
related anatomical obstacles stabilize and organize AT, preventing wavebreak. Therefore, pre-
sentation as AT or AF might be determined by atrial pathology and degree of remodeling with
bimodal pattern.
Limitations
The present study has several limitations. First, the study has a retrospective observational
design. Second, the recurrence pattern can be affected by the ablation lesion set. Although a
consistent ablation lesion set was maintained by two experienced operators, ablation lesion
was different between patients with paroxysmal AF and those with persistent AF. Third, since
we included patients who experienced recurrence, bidirectional block rates of de novo linear
ablations were relatively lower in this study compared to previous reports.[4] In the overall
cohort, bidirectional block rates for anterior line and roof line were 64% and 85%, respectively.
[26] Forth, a relatively small proportion of patients with recurrence, who were resistant to anti-
arrhythmic drug therapy, underwent redo ablation. Fifth, in order to include a large number
of recurred patients who were not taking antiarrhythmic drugs, we analyzed both early and
late recurrence. However, the sub-analysis result of patients with late recurrence (n = 269) was
consistent with the result of the overall patients (Table 4). Sixth, LA bipolar voltage maps were
analyzable in 68.1% (355 of 521) of included patients.
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Conclusion
Although the electrical gap due to incomplete conduction block was suggested to be an impor-
tant mechanism of recurrent AT after AF ablation, the degree of LA remodeling is significantly
associated with recurrent AT after AF ablation, irrespective of potential ablation gap.
Author Contributions
Conceptualization: Hui-Nam Pak.
Data curation: Pil-Sung Yang, Young-Ah Park, Tae-Hoon Kim, Jae-Sun Uhm, Boyoung
Joung, Moon-Hyoung Lee, Hui-Nam Pak.
Formal analysis: Pil-Sung Yang, Young-Ah Park.
Funding acquisition: Hui-Nam Pak.
Supervision: Hui-Nam Pak.
Writing – original draft: Pil-Sung Yang, Young-Ah Park.
References
1. Tzou WS, Marchlinski FE, Zado ES, Lin D, Dixit S, Callans DJ, et al. Long-term outcome after success-
ful catheter ablation of atrial fibrillation. Circ Arrhythm Electrophysiol. 2010; 3(3):237–242. https://doi.
org/10.1161/CIRCEP.109.923771 PMID: 20335557.
2. Patel AM, d’Avila A, Neuzil P, Kim SJ, Mela T, Singh JP, et al. Atrial tachycardia after ablation of persis-
tent atrial fibrillation: identification of the critical isthmus with a combination of multielectrode activation
mapping and targeted entrainment mapping. Circ Arrhythm Electrophysiol. 2008; 1(1):14–22. https://
doi.org/10.1161/CIRCEP.107.748160 PMID: 19808389.
3. Veenhuyzen GD, Knecht S, O’Neill MD, Phil D, Wright M, Nault I, et al. Atrial tachycardias encountered
during and after catheter ablation for atrial fibrillation: part I: classification, incidence, management. Pac-
ing Clin Electrophysiol. 2009; 32(3):393–398. Epub 2009/03/11. https://doi.org/10.1111/j.1540-8159.
2008.02250.x PMID: 19272072.
4. Knecht S, Hocini M, Wright M, Lellouche N, O’Neill MD, Matsuo S, et al. Left atrial linear lesions are
required for successful treatment of persistent atrial fibrillation. Eur Heart J. 2008; 29(19):2359–2366.
Epub 2008/07/11. https://doi.org/10.1093/eurheartj/ehn302 PMID: 18614522.
5. Anousheh R, Sawhney NS, Panutich M, Tate C, Chen WC, Feld GK. Effect of mitral isthmus block on
development of atrial tachycardia following ablation for atrial fibrillation. Pacing Clin Electrophysiol.
2010; 33(4):460–468. Epub 2009/12/04. https://doi.org/10.1111/j.1540-8159.2009.02625.x PMID:
19954501.
6. Haissaguerre M, Sanders P, Hocini M, Takahashi Y, Rotter M, Sacher F, et al. Catheter ablation of
long-lasting persistent atrial fibrillation: critical structures for termination. J Cardiovasc Electrophysiol.
2005; 16(11):1125–1137. Epub 2005/11/24. https://doi.org/10.1111/j.1540-8167.2005.00307.x PMID:
16302892.
7. Haissaguerre M, Hocini M, Sanders P, Sacher F, Rotter M, Takahashi Y, et al. Catheter ablation of
long-lasting persistent atrial fibrillation: clinical outcome and mechanisms of subsequent arrhythmias. J
Cardiovasc Electrophysiol. 2005; 16(11):1138–1147. https://doi.org/10.1111/j.1540-8167.2005.00308.
x PMID: 16302893.
8. Hwang ES, Nam GB, Joung B, Park J, Lee JS, Shim J, et al. Significant reduction of atrial defibrillation
threshold and inducibility by catheter ablation of atrial fibrillation. Pacing Clin Electrophysiol. 2012; 35
(12):1428–1435. Epub 2012/09/18. https://doi.org/10.1111/j.1540-8159.2012.03517.x PMID:
22978799.
9. Park JH, Pak HN, Choi EJ, Jang JK, Kim SK, Choi DH, et al. The relationship between endocardial volt-
age and regional volume in electroanatomical remodeled left atria in patients with atrial fibrillation: com-
parison of three-dimensional computed tomographic images and voltage mapping. J Cardiovasc
Electrophysiol. 2009; 20(12):1349–1356. Epub 2009/07/16. https://doi.org/10.1111/j.1540-8167.2009.
01557.x PMID: 19602027.
10. Heck PM, Rosso R, Kistler PM. The challenging face of focal atrial tachycardia in the post AF ablation
era. J Cardiovasc Electrophysiol. 2011; 22(7):832–838. https://doi.org/10.1111/j.1540-8167.2011.
02090.x PMID: 21635611.
Recurrence as AT after AF ablation
PLOS ONE | https://doi.org/10.1371/journal.pone.0188326 November 16, 2017 11 / 12
11. Won H, Uhm JS, Shim J, Joung B, Lee MH, Pak HN. The effectiveness of anti-arrhythmic drugs on
recurrent atrial tachyarrhythmias after catheter ablation of atrial fibrillation. Int J Cardiol. 2013; 168
(2):1570–1572. Epub 2013/03/08. https://doi.org/10.1016/j.ijcard.2013.01.186 PMID: 23465248.
12. Calkins H, Kuck KH, Cappato R, Brugada J, Camm AJ, Chen SA, et al. 2012 HRS/EHRA/ECAS Expert
Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation: recommendations for
patient selection, procedural techniques, patient management and follow-up, definitions, endpoints,
and research trial design. Europace. 2012; 14(4):528–606. Epub 2012/03/06. https://doi.org/10.1093/
europace/eus027 PMID: 22389422.
13. Kim TH, Park J, Park JK, Uhm JS, Joung B, Lee MH, et al. Pericardial fat volume is associated with clini-
cal recurrence after catheter ablation for persistent atrial fibrillation, but not paroxysmal atrial fibrillation:
an analysis of over 600-patients. Int J Cardiol. 2014; 176(3):841–846. Epub 2014/09/02. https://doi.org/
10.1016/j.ijcard.2014.08.008 PMID: 25176630.
14. Jais P, Matsuo S, Knecht S, Weerasooriya R, Hocini M, Sacher F, et al. A deductive mapping strategy
for atrial tachycardia following atrial fibrillation ablation: importance of localized reentry. J Cardiovasc
Electrophysiol. 2009; 20(5):480–491. https://doi.org/10.1111/j.1540-8167.2008.01373.x PMID:
19207747.
15. Moe GK, Rheinboldt WC, Abildskov JA. A Computer Model of Atrial Fibrillation. Am Heart J. 1964;
67:200–220. Epub 1964/02/01. PMID: 14118488.
16. Kim YH, Garfinkel A, Ikeda T, Wu TJ, Athill CA, Weiss JN, et al. Spatiotemporal complexity of ventricular
fibrillation revealed by tissue mass reduction in isolated swine right ventricle. Further evidence for the
quasiperiodic route to chaos hypothesis. J Clin Invest. 1997; 100(10):2486–2500. Epub 1997/11/20.
https://doi.org/10.1172/JCI119791 PMID: 9366563.
17. Lee AM, Aziz A, Didesch J, Clark KL, Schuessler RB, Damiano RJ Jr. Importance of atrial surface area
and refractory period in sustaining atrial fibrillation: testing the critical mass hypothesis. J Thorac Cardio-
vasc Surg. 2013; 146(3):593–598. Epub 2012/09/22. https://doi.org/10.1016/j.jtcvs.2012.04.021 PMID:
22995722.
18. Hwang M, Park J, Lee YS, Park JH, Choi SH, Shim EB, et al. Fibrillation number based on wavelength
and critical mass in patients who underwent radiofrequency catheter ablation for atrial fibrillation. IEEE
Trans Biomed Eng. 2015; 62(2):673–679. Epub 2014/10/25. https://doi.org/10.1109/TBME.2014.
2363669 PMID: 25343755.
19. Marrouche NF, Wilber D, Hindricks G, Jais P, Akoum N, Marchlinski F, et al. Association of atrial tissue
fibrosis identified by delayed enhancement MRI and atrial fibrillation catheter ablation: the DECAAF
study. Jama. 2014; 311(5):498–506. Epub 2014/02/06. https://doi.org/10.1001/jama.2014.3 PMID:
24496537.
20. Takahashi Y, Takahashi A, Miyazaki S, Kuwahara T, Takei A, Fujino T, et al. Electrophysiological char-
acteristics of localized reentrant atrial tachycardia occurring after catheter ablation of long-lasting per-
sistent atrial fibrillation. J Cardiovasc Electrophysiol. 2009; 20(6):623–629. Epub 2009/02/12. https://
doi.org/10.1111/j.1540-8167.2008.01410.x PMID: 19207768.
21. Lau DH, Mackenzie L, Kelly DJ, Psaltis PJ, Brooks AG, Worthington M, et al. Hypertension and atrial
fibrillation: evidence of progressive atrial remodeling with electrostructural correlate in a conscious
chronically instrumented ovine model. Heart Rhythm. 2010; 7(9):1282–1290. Epub 2010/05/15. https://
doi.org/10.1016/j.hrthm.2010.05.010 PMID: 20466075.
22. Okin PM, Wachtell K, Devereux RB, Harris KE, Jern S, Kjeldsen SE, et al. Regression of electrocar-
diographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation in patients
with hypertension. Jama. 2006; 296(10):1242–1248. Epub 2006/09/14. https://doi.org/10.1001/jama.
296.10.1242 PMID: 16968848.
23. Gerdts E, Wachtell K, Omvik P, Otterstad JE, Oikarinen L, Boman K, et al. Left atrial size and risk of
major cardiovascular events during antihypertensive treatment: losartan intervention for endpoint
reduction in hypertension trial. Hypertension. 2007; 49(2):311–316. Epub 2006/12/21. https://doi.org/
10.1161/01.HYP.0000254322.96189.85 PMID: 17178978.
24. Shim CY, Park S, Choi D, Yang WI, Cho IJ, Choi EY, et al. Sex differences in central hemodynamics
and their relationship to left ventricular diastolic function. J Am Coll Cardiol. 2011; 57(10):1226–1233.
Epub 2011/03/05. https://doi.org/10.1016/j.jacc.2010.09.067 PMID: 21371640.
25. Park J, Yang PS, Kim TH, Uhm JS, Kim JY, Joung B, et al. Low Left Atrial Compliance Contributes to
the Clinical Recurrence of Atrial Fibrillation after Catheter Ablation in Patients with Structurally and
Functionally Normal Heart. PLoS One. 2015; 10(12):e0143853. Epub 2015/12/02. https://doi.org/10.
1371/journal.pone.0143853 PMID: 26624617.
26. Kim TH, Park J, Uhm JS, Kim JY, Joung B, Lee MH, et al. Challenging Achievement of Bidirectional
Block After Linear Ablation Affects the Rhythm Outcome in Patients With Persistent Atrial Fibrillation. J
Am Heart Assoc. 2016; 5(10). Epub 2016/10/30. https://doi.org/10.1161/jaha.116.003894 PMID:
27792644.
Recurrence as AT after AF ablation
PLOS ONE | https://doi.org/10.1371/journal.pone.0188326 November 16, 2017 12 / 12
